Saccomano Nicholas A 的 Form 4 申報
OnKure Therapeutics, Inc.（OKUR），2026/8/11 申報
- 申報編號
- 0001609284-26-000004
- 申報時間
- 2026/8/11 16:27 ET
- 交易日
- 2026/8/7
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 11 筆衍生性交易。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Saccomano Nicholas ACIK 0001609284 | 董事、高階主管（總裁、執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/7 | Class A Common Stock | A公司授予取得 | +150,000 | $0.00 | $0 | 150,000 | 直接 | |
| 2026/8/7 | Class A Common Stock | D交回公司處分 | −2,359 | –F3,F4 | – | 0 | 直接 | |
| 2026/8/7 | Class A Common Stock | A公司授予取得 | +2,359 | –F3,F4 | – | 2,359 | 直接 | |
| 2026/8/7 | Class A Common Stock | D交回公司處分 | −1,485 | –F3,F4 | – | 0 | 直接 | |
| 2026/8/7 | Class A Common Stock | A公司授予取得 | +1,485 | –F3,F4 | – | 1,485 | 直接 | |
| 2026/8/7 | Class A Common Stock | D交回公司處分 | −8,449 | –F3,F4 | – | 0 | 直接 | |
| 2026/8/7 | Class A Common Stock | A公司授予取得 | +8,449 | –F3,F4 | – | 8,449 | 直接 | |
| 2026/8/7 | Class A Common Stock | D交回公司處分 | −16,898 | –F3,F4 | – | 0 | 直接 | |
| 2026/8/7 | Class A Common Stock | A公司授予取得 | +16,898 | –F3,F4 | – | 16,898 | 直接 | |
| 2026/8/7 | Class A Common Stock | D交回公司處分 | −542,232 | –F3,F4 | – | 0 | 直接 | |
| 2026/8/7 | Class A Common Stock | A公司授予取得 | +542,232 | –F3,F4 | – | 542,232 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
表 II 有 10 筆交易的價格引用這則附註。
- F4
Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
表 II 有 10 筆交易的價格引用這則附註。